natgillin/translations-raw huggingface dataset:
No major age-related differences in clearance or volume of distribution were observed in clinical studies with infliximab intravenous formulations and the same is expected for subcutaneous formulation. 
V kliničnih študijah z infliksimabom v intravenski obliki niso opazili nikakršnih večjih, s starostjo povezanih razlik v očistku ali porazdelitvenem volumnu, enako se predvideva za infliksimab v subkutani obliki.
Remsima is supplied as a glass vial containing a powder for concentrate for solution for infusion. 
Zdravilo Remsima je na voljo v steklenih vialah s praškom za koncentrat za raztopino za infundiranje.
c. Gently press a cotton ball or gauze over the injection site and apply an adhesive bandage, if necessary. 
c. Kosem vate ali gazo nežno pritisnite na mesto injiciranja in ga po potrebi prelepite z obližem.
• Tell your doctor before you are using Remsima if you are a carrier of hepatitis B or have ever had it. 
• Preden uporabite zdravilo Remsima, povejte zdravniku, če ste prenašalec hepatitisa B ali če ste ga imeli kdaj v preteklosti.
Week 22 137 (78.7%) 139 (84.2%) 90 (51.7%) 85 (51.5%) 49 (28.2%) 46 (27.9%) 
6. teden 103 (59,2 %) 107 (64,8 %) 45 (25,9 %) 47 (28,5 %) 18 (10,3 %) 19 (11,5 %) 22. teden 137 (78,7 %) 139 (84,2 %) 90 (51,7 %) 85 (51,5 %) 49 (28,2 %) 46 (27,9 %) 54. teden 125 (71,8 %)a 132 (80,0 %) 101 (58,0 %)a 108 (65,5 %) 68 (39,1 %)a 77 (46,7 %) a
Placebo Maintenance (n=99) 
Vzdrževalno zdravljenje s placebom (n=110)
• Signs of an immune system disorder called lupus such as joint pain or a rash on cheeks or arms that is sensitive to the sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis). 
• znaki motnje v delovanju imunskega sistema, na primer bolečina v sklepih ali izpuščaj na licih ali rokah, ki je občutljiv na sončno svetlobo (lupus), ali kašelj, kratka sapa, zvišana telesna temperatura ali kožni izpuščaj (sarkoidoza).
Concomitant administration of immunomodulators has been associated with lower incidence of antibodies to infliximab and in the case of intravenously administered infliximab, a reduction in the frequency of infusion reactions. 
Sočasna uporaba imunomodulatorjev je bila povezana z zmanjšano incidenco protiteles na infliksimab in v primeru intravenskega dajanja infliksimaba tudi z zmanjšanjem pogostnosti z infuzijo povezanih reakcij.
Excipients: sucrose, polysorbate 80, sodium dihydrogen phosphate monohydrate, disodium phosphate dihydrate. 
Pomožne snovi: saharoza, polisorbat 80, natrijev dihidrogenfosfat monohidrat, natrijev hidrogenfosfat dihidrat.
Circulatory failure, petechia, vasospasm Respiratory, thoracic and mediastinal disorders Very common 
odpoved krvnega obtoka, petehija, vazospazem Bolezni dihal, prsnega koša in mediastinalnega prostora zelo pogosti:
If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Remsima. 
Če niste prepričani, ali kaj od naštetega velja za vas, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden boste prejeli zdravilo Remsima.
Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis (LABD), lichenoid reactions, acute generalised exanthematous pustulosis (AGEP). 
multiformni eritem, furunkuloza, linearna IgA bulozna dermatoza (LABD), lihenoidne reakcije, akutna generalizirana eksantematozna pustuloza (AGEP - acute generalised exanthematous pustulosis).
Keep the medicinal product in its outer carton in order to protect from light. 
Zdravilo shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Can be stored at room temperature (up to 25°C) for a single period up to 6 months, but not exceeding the original expiry date. 
Lahko se shranjuje pri sobni temperaturi (do 25 °C) za enkratno obdobje do 6 mesecev, vendar ne dlje od originalnega datuma izteka roka uporabnosti.
Post-marketing spontaneous serious adverse reactions with infliximab in the paediatric population have included malignancies including hepatosplenic T-cell lymphomas, transient hepatic enzyme abnormalities, lupus-like syndromes, and positive auto-antibodies (see sections 4.4 and 4.8). 
Med spontano poročanimi resnimi neželenimi učinki v obdobju trženja z uporabo infliksimaba iz obdobja trženja pri pediatričnih bolnikih so bili tudi malignomi, vključno s T-celičnimi limfomi jeter in vranice, prehodno nenormalnimi izvidi jetrnih encimov, lupusu podobnimi sindromi in pozitivnimi izvidi na avtoprotitelesa (glejte poglavji 4.4 in 4.8).
Finish the injection (see Figure G). 
Končajte injiciranje (glejte sliko G).
• The abdomen except for the 5 cm around the belly button (navel). 
• Trebuh, razen na področju, ki je od vašega popka oddaljeno manj kot 5 centimetrov.
Cardiac failure (new onset or worsening), arrhythmia, syncope, bradycardia 
srčno popuščanje (novo nastalo ali poslabšanje), aritmija,
• upright and stable during use; 
• je med uporabo v pokončnem in stabilnem položaju; • je odporen na iztekanje in
What you need to know before you use Remsima You must not use Remsima if 
Kaj morate vedeti, preden boste uporabili zdravilo Remsima Ne uporabljajte zdravila Remsima
Hepatic and renal impairment 
Jetrna in ledvična bolezen
178 of the 580 enrolled patients (30.7%) were defined as having severe disease (CDAI score > 300 and concomitant corticosteroid and/or immunosuppressants) corresponding to the population defined in the indication (see section 4.1). 
so ugotovili hudo obliko bolezni (ocena CDAI > 300 in sočasna uporaba kortikosteroidov in /ali imunosupresivov), kar ustreza populaciji, opredeljeni v indikacijah (glejte poglavje 4.1).
The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess. 
Najpogosteje prijavljene okužbe so bile okužbe zgornjih dihal in faringitis,
In the re-treatment arm, 4% (8/219) of patients experienced a serious infusion reaction versus <1% (1/222) on maintenance therapy. 
V kraku za ponovno zdravljenje so imeli 4 % bolnikov (8/219) resno z infuzijo povezano reakcijo, v primerjavi z
• Other skin problems such as erythema multiforme, blisters and peeling skin, or boils (furunculosis) 
• ostale težave s kožo, kot so multiformni eritem, mehurji na koži in luščenje kože, ali turi (furunkuloza)
Hypotension, hypertension, ecchymosis, hot flush, flushing 
hipotenzija, hipertenzija, ekhimoza, navali vročine, zardevanje občasni:
Concomitant administration of immunomodulators has been associated with lower incidence of antibodies to infliximab and a reduction in the frequency of infusion reactions. 
Sočasna uporaba imunomodulatorjev je bila povezana z zmanjšano incidenco protiteles na infliksimab in zmanjšanjem pogostnosti z infuzijo povezanih reakcij.
However, studies from the published literature in various indications (e.g. rheumatoid arthritis, psoriasis, Crohn's disease) suggest that non-live vaccinations received during treatment with anti-TNF therapies, including infliximab may elicit a lower immune response than in patients not receiving anti-TNF therapy. 
Vseeno pa študije iz objavljene literature za različne indikacije (npr. revmatoidni artritis, psoriaza, Crohnova bolezen) nakazujejo, da cepljenja z neživimi cepivi med prejemanjem anti
What you need to know before you use Remsima You must not be given Remsima if 
Kaj morate vedeti, preden boste uporabili zdravilo Remsima Zdravila Remsima ne smete dobivati
Almost all patients had received treatment with AZA or 6-MP concomitantly with or immediately prior to a TNF-blocker. 
AZA ali 6-MP, bodisi sočasno z zaviralcem TNF ali neposredno pred uporabo zaviralca TNF.
• When starting a new card, keep this card as a reference for 4 months after your last dose of Remsima. 
• Ko prejmete novo kartico, imejte to kartico pri sebi še 4 mesece po zadnjem odmerku zdravila Remsima.
Choose an injection site (see Figure C). 
Izberite mesto injiciranja (glejte sliko C).
Remsima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. 
Zdravilo Remsima je indicirano za zdravljenje zmerno do močno aktivnega ulceroznega kolitisa pri odraslih bolnikih, ki so se nezadostno odzvali na običajno zdravljenje, na primer na kortikosteroide in 6-merkaptopurin (6-MP) ali azatioprin (AZA), ter pri tistih, ki ne prenašajo takšnega zdravljenja ali imajo medicinske kontraindikacije zanj.
The required volume of the reconstituted Remsima solution should be diluted to 250 mL with sodium chloride 9 mg/mL (0.9%) solution for infusion. 
Potrebni volumen rekonstituirane raztopine zdravila Remsima razredčite do 250 ml z 9 mg/ml
Upper respiratory tract infection, sinusitis 
okužba zgornjih dihal, sinusitis pogosti:
Maintenance treatment in fistulising active Crohn's disease The efficacy of repeated infusions with infliximab in patients with fistulising Crohn's disease was studied in a 1-year clinical study (ACCENT II). 
Učinkovitost večkratnih infuzij infliksimaba pri bolnikih s Crohnovo boleznijo s fistulami so raziskovali v enoletni klinični študiji (ACCENT II).
• Tell your doctor before you are given Remsima if you have a lung disease called chronic obstructive pulmonary disease (COPD) or if you are a heavy smoker. 
Pljučna bolezen ali bolniki, ki veliko kadijo • Preden prejmete zdravilo Remsima, povejte zdravniku, če imate kronično obstruktivno pljučno bolezen (KOPB) ali če veliko kadite.
3 Number of patients evaluated for ALT. 4 Median follow-up is based on patients treated. 
4 Mediana dolžine spremljanja bolnikov je bila določena samo z upoštevanjem zdravljenih bolnikov.
If you are not sure, talk to your doctor before you are given Remsima. 
Če ste negotovi, se posvetujte z zdravnikom, preden začnete prejemati zdravilo Remsima.
Clinical Responsea 
Klinični odziva Klinična remisija
It is recommended that the conduct of these tests should be recorded in the patient reminder card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised. 
Zdravnike opozarjamo, da so izvidi tuberkulinskega kožnega testa lahko lažno negativni, še posebej pri bolnikih, ki so močno bolni ali imajo zmanjšan imunski odziv.
Rheumatoid arthritis1 
Revmatoid ni artritis1
In rheumatoid arthritis patients, there are indications that concomitant use of methotrexate and other immunomodulators reduces the formation of antibodies against infliximab and increases the plasma concentrations of infliximab. 
Sočasna uporaba metotreksata in drugih imunomodulatorjev pri bolnikih z revmatoidnim artritisom lahko zmanjša tvorbo protiteles proti infliksimabu in poveča koncentracijo infliksimaba v plazmi.
In this situation, infliximab should be re-initiated as a single dose followed by the maintenance dose recommendations described above. 
V tem primeru bolniku najprej ponovno uvedite zdravilo Remsima v enkratnem odmerku, pozneje pa mu spet predpišite vzdrževalni odmerek zdravila v skladu s priporočili, ki so podana zgoraj.
Mucosal healing at Week 30a a p <0.001, for each infliximab treatment group vs. placebo. 
Celjenje sluznice v 30. tednua a p < 0,001 za vsako skupino, ki se je zdravila z infliksimabom, v primerjavi s placebom
If these medicines do not work well enough, you will be given Remsima which you will take with another medicine called methotrexate to: 
Če ta zdravila ne delujejo dovolj dobro, boste prejeli zdravilo Remsima skupaj z zdravilom metotreksat za:
a. After the needle is inserted, let go of the pinched skin. 
a. Ko vstavite iglo, spustite kožo, ki jo držite.
Remove the pen from the injection site. 
Injekcijski peresnik umaknite z mesta injiciranja.
• Changes in how your liver works, increase in liver enzymes (shown in blood tests) 
Pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov • spremenjeno delovanje vaših jeter, povečanje vrednosti jetrnih encimov (pokaže se v izvidih krvnih preiskav)
Start the injection (see Figure F). 
Začnite injiciranje (glejte sliko F).
Remsima contains sodium 
Zdravilo Remsima vsebuje natrij
Do not touch the needle cover. 
Ne prijemajte zaščite igle.
Patients randomised 
Starejši bolniki
• Other skin problems such as erythema multiforme, blisters and peeling skin, or boils 
• ostale težave s kožo, kot so multiformni eritem, mehurji na koži in luščenje kože, ali turi
Do not use the syringe if the liquid is different to clear colourless or pale brown or contains particles in it. 
Injekcijskega peresnika ne smete uporabiti, če tekočina ni bistra ali bledo rjava ali če so v njej prisotni neprosojni delci.
• Fungal infections such as yeast infection, or fungal infection of the nails 
• glivične okužbe, na primer okužba s kvasovkami ali glivična okužba nohtov
Clinical remission and mucosal healing occurred in a greater proportion of patients in the combined infliximab treatment group compared to the placebo treatment group at week 54 (34.6% vs. 16.5%, p<0.001 and 46.1% vs. 18.2%, p<0.001, respectively). 
Klinično remisijo in celjenje sluznice v 54. tednu so ugotovili pri večjem odstotku bolnikov v (združeni) skupini, ki se je zdravila z infliksimabom, kot pa v skupini, ki je prejemala placebo (34,6 % v primerjavi s 16,5 %; p< 0,001, in 46,1 % v primerjavi z 18,2 %; p< 0,001).
Type 1 glass vial with a (butyl) rubber stopper and an aluminium seal with a flip-off button. 
Viala (steklo tipa 1) z gumijastim zamaškom in aluminijasto zaporko, zaščiteno s plastično ploščico,
Remsima and Kineret should not be used together. 
Zdravili Remsima in Kineret se ne smeta uporabljati skupaj.
The syringe is made from type I glass with a plunger stopper (flurotec-coated elastomer) and needle with a rigid needle shield. 
Injekcijska brizga je izdelana iz stekla tipa I z batnim zamaškom (iz elastomera s prevleko Flurotec) in iglo s trdim ščitnikom za iglo.
If these medicines do not work well enough, you will be given Remsima to: 
Če ta zdravila ne delujejo dovolj dobro, boste prejeli zdravilo Remsima za:
Gastrointestinal haemorrhage, diarrhoea, dyspepsia, gastroesophageal reflux, constipation 
krvavitev iz prebavil, driska, dispepsija, gastroezofagealni refluks, zaprtje občasni:
In addition: 
Remsima:
Patients treated with Remsima should be given the package leaflet and the patient reminder card. 
Bolniki, zdravljeni z zdravilom Remsima, morajo prejeti navodilo za uporabo in opozorilno kartico za bolnika.
• After proper training, if you feel you are well-trained and confident to inject Remsima yourself, your doctor may allow you to inject subsequent doses of Remsima yourself at home. 
• Po ustreznem usposabljanju vam bo morda zdravnik dovolil, da si naknadne odmerke zdravila
The following side effects have been observed with Remsima: 
Pri uporabi zdravila Remsima so opazili naslednje neželene učinke:
Powder for concentrate for solution for infusion (powder for concentrate) The powder is white. 
prašek za koncentrat za raztopino za infundiranje (prašek za koncentrat).
Upper respiratory tract infection was the most common adverse drug reaction (ADR) reported in clinical trials with infliximab, occurring in 25.3% of infliximab-treated patients compared with 16.5% of control patients. 
Najpogostejši neželeni učinek zdravila, o katerem so poročali v kliničnih preskušanjih z infliksimabom, je bila okužba zgornjih dihal, ki se je pojavila pri 25,3 % bolnikov, zdravljenih z infliksimabom, in pri 16,5 % bolnikov iz kontrolne skupine.
• Ankylosing spondylitis (Bechterew's disease) 
• Psoriatični artritis • Ankilozirajoči sponzilitis (Bechterew sindrom)
• The medicine will be given as an infusion (drip) (over 2 hours) into one of your veins, usually in your arm. After the third treatment, your doctor may decide to give your dose of Remsima over 
• Zdravilo vam bodo dali v obliki infuzije (kapalne) (v času 2 ur) v eno od ven, običajno v roki.
Juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis The safety and efficacy of infliximab in children and adolescents younger than 18 years for the indications of juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not been established. 
Varnost in učinkovitost infliksimaba pri otrocih in mladostnikih, mlajših od 18 let, za indikacije juvenilni idiopatski artritis, psoriatični artritis in ankilozirajoči spondilitis nista bili dokazani.
EU/1/13/853/001 1 vial EU/1/13/853/002 2 vials EU/1/13/853/003 3 vials EU/1/13/853/004 4 vials EU/1/13/853/005 5 vials 
EU/1/13/853/0011 viala EU/1/13/853/002 2 viali EU/1/13/853/003 3 viale EU/1/13/853/004 4 viale EU/1/13/853/005 5 vial
• You should avoid getting pregnant when you are being treated with Remsima and for 6 months after you stop being treated with it. 
• Če prejemate zdravilo Remsima, je treba preprečiti nosečnost med zdravljenjem in še vsaj 6 mesecev po prenehanju zdravljenja.
About the Remsima syringe Parts of the syringe (see Figure A): 
Informacije o peresniku Remsima Sestavni deli injekcijskega peresnika (glejte sliko A):
When starting a new card, please keep this card as a reference for 4 months after your last dose of Remsima. 
Ko prejmete novo kartico, imejte to kartico pri sebi še 4 mesece po zadnjem odmerku zdravila Remsima.
Note: When the injection starts you will hear the 1st loud 
Opomba: Ob začetku injiciranja boste zaslišali glasen prvi »klik«, nato pa boste skozi okence videli, kako olivno zelen bat brizge napreduje.
Insert the syringe into the injection site (see Figure E). 
Injekcijsko brizgo položite na mesto injiciranja (glejte sliko E).
Pulmonary oedema, bronchospasm, pleurisy, pleural effusion 
pljučni edem, bronhospazem, plevritis, plevralni izliv redki:
All randomised patients 
Število randomiziranih bolnikov
Clinical Remission 
KLINIČNI PODATKI
Remsima 120 mg solution for injection in pre-filled syringe or in pre-filled pen are administered by subcutaneous injection only. 
Zdravilo Remsima 120 mg raztopina za injiciranje v napolnjeni injekcijski brizgi ali v napolnjenem injekcijskem peresniku se lahko aplicira samo s subkutanim injiciranjem.
• Cotton ball or gauze* 
• Kosem vate ali gazo*
Transient visual loss occurring during or within 2 hours of infusion 
prehodna izguba vida, ki nastopi med infundiranjem ali v roku 2 ur po infundiranju
• This medicine can also be stored in the original carton outside of refrigerated storage up to a maximum of 25°C for a single period of up to 14 days, but not beyond the original expiry date. 
• To zdravilo se lahko shranjuje tudi v originalni škatli izven hladilnika do največ 25 °C za enkratno obdobje do 14 dni, vendar ne dlje od originalnega datuma izteka roka uporabnosti.
2 Number of patients evaluated for ALT. 3 Median follow-up is based on patients treated. 
3 Mediana dolžine spremljanja bolnikov je bila določena samo z upoštevanjem zdravljenih bolnikov.
• Do not use the pen if it has been dropped or is visibly damaged. 
• Injekcijski peresnika ne smete uporabiti, če je padel na tla ali če ima vidne znake poškodb.
• Signs of a heart problem such as chest discomfort or pain, arm pain, stomach pain, shortness of breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea (feeling sick), 
• znaki težav s srcem, na primer nelagodje ali bolečina v prsnem košu, bolečina v roki, bolečina v trebuhu, kratka sapa, tesnoba, vrtoglavica, omotica, omedlevica, potenje, siljenje na bruhanje
• Signs of a local injection site reaction such as redness, pain, itching, swelling, hardness, bleeding, bruising, cold sensation, irritation, tingling sensation, ulcer, hives, rash and scab. 
• znaki lokalne reakcije na mestu injiciranja, kot so rdečica, bolečina, srbečica, oteklina, otrdelost, krvavitev, modrice, občutek hlada, draženje, občutek ščemenja, ulkus, koprivnica, izpuščaj in krasta.
Remsima is a solution that is clear to opalescent, colourless to pale brown. 
Zdravilo Remsima je bistra do opalescentna in brezbarvna do bledo rjava raztopina.
There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates risk estimation. 
močno aktivno vnetno bolezen, je osnovno tveganje za limfom in levkemijo povečano, kar dodatno zaplete oceno tveganja.
At single doses of 3, 5, or 10 mg/kg, the median Cmax values were 77, 118 and 277 micrograms/mL, respectively. 
Cmaks 77, 118 in 277 mikrogramov/ml.
Paediatric ulcerative colitis patients 
Pediatrični bolniki z ulceroznim kolitisom
Table 5 Effects on response and remission rate, data from ACCENT I (Week-2 responders) 
Učinki na stopnjo odziva in ponovitev bolezni pri bolnikih; podatki iz študije ACCENT I
Rheumatoid arthritis1 1 Placebo patients received methotrexate while infliximab patients received both infliximab and methotrexate. 
1 Bolniki iz placebo skupine so prejemali metotreksat, medtem ko so bolniki iz skupine infliksimab prejemali tako infliksimab kot metotreksat.
Tell your doctor straight away if you get signs of infection during treatment with Remsima. 
Zdravniku takoj povejte, če ste dobili simptome okužbe med zdravljenjem z zdravilom Remsima.
Remsima may be stored at temperatures up to a maximum of 25°C for a single period of up to 6 months, but not exceeding the original expiry date. 
Zdravilo Remsima se lahko shranjuje pri temperaturah do največ 25°C za enkratno obdobje do 6 mesecev, vendar ne dlje od originalnega datuma izteka roka uporabnosti.
(anaphylactic shock) 
(hepatosplenični limfom T celic)
Remsima 120 mg injection infliximab 
Remsima 120 mg injekcija infliksimab s.c.
Do not use if the solution is cloudy, discoloured or contains visible particulate matter. 
Raztopine ne smete uporabiti, če je motna, razbarvana ali če so prisotni neprosojni delci.
Clinical Responsea Clinical Remission Steroid-Free Remission 
Remisija brez jemanja steroidov
Cases of jaundice and non-infectious hepatitis, some with features of autoimmune hepatitis, have been observed in the post-marketing experience of infliximab. 
V obdobju trženja so opazili primere zlatenice in neinfekcijskega hepatitisa in nekateri od njih so imeli značilnosti avtoimunskega hepatitisa.
Remsima is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies. 
Ulcerozni kolitis pri pediatričnih bolnikih Zdravilo Remsima je indicirano za zdravljenje močno aktivnega ulceroznega kolitisa pri otrocih in mladostnikih, starih od 6 do 17 let, ki so se nezadostno odzvali na običajno zdravljenje, na primer na kortikosteroide in 6-MP ali AZA, ter pri tistih, ki ne prenašajo takšnega zdravljenja ali imajo medicinske kontraindikacije zanj.
• This medicine can also be stored in the original carton outside of refrigerated storage up to a maximum of 25°C for a single period of up to six months, but not beyond the original expiry date. 
• To zdravilo se lahko shranjuje tudi v originalni škatli izven hladilnika do največ 25 °C za enkratno obdobje do 6 mesecev, vendar ne dlje od originalnega datuma izteka roka uporabnosti.
Each pack contains 1 pre-filled syringe with automatic needle guard with 2 alcohol pads, 2 pre-filled syringes with automatic needle guard with 2 alcohol pads or 4 pre-filled syringes with automatic needle guard with 4 alcohol pads. 
Eno pakiranje vsebuje 1 napolnjeno injekcijsko brizgo s samodejnim ščitnikom za iglo z 2 alkoholnima zložencema, 2 napolnjeni injekcijski brizgi s samodejnim ščitnikom za iglo z 2 alkoholnima zložencema ali 4 napolnjene injekcijske igle s samodejnim ščitnikom za iglo s 4 alkoholnimi zloženci.